Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Talia Golan, MD, regarding the practice-changing potential of the POLO trial

Dr. Golan, Head of Sheba Pancreatic Cancer Center, regarding the practice-changing potential of the POLO trial investigating maintenance with olaparib in metastatic pancreatic cancer

Tags: ASCO Conference CoveragePancreatic

Published: 04 June 2019

Recent Videos

video

Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer

Dr. Thierry, Professor of Medical Oncology, Sorbonne Universites, discusses the evolution of I-O towards the first line treatment in colorectal ...

video

Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely respond to I-O

Dr. Andre, Professor of Medical Oncology, Sorbonne Universites, provides thoughts on how to identify patients with colorectal cancer that are ...

video

Thierry Andre, MD, shares design of the Keynote-177 study in metastatic colorectal cancer

Dr. Andre, Professor of Medical Oncology, Sorbonne Universites, shares the design of the Keynote-177 study investigating the use of pembrolizumab ...

video

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

Dr. Galsky, Professor, Mount Sinai School of Medicine, discusses how to identify patients that will likely be good responders and ...

video

Matthew Galsky, MD, considers a new standard of maintenance with the Javelin study outcomes

Dr. Galsky, Professor, Mount Sinai School of Medicine, considers whether the outcomes of the Javelin Bladder 100 study are compelling ...

video

Matthew Galsky, MD, shares the design and outcomes of the Javelin Bladder 100 study

Dr. Galsky, Professor, Mount Sinai School of Medicine, shares the design and outcomes of the Javelin Bladder 100 study investigating ...

video

Matthew Galsky, MD, explains which biomarkers likely have the most predictive value

Dr. Galsky, Professor, Mount Sinai School of Medicine, explains which biomarkers likely have the most predictive value when treating metastatic ...

video

Matthew Galsky, MD, tells us about the Phase 3 IMvigor130 study in advanced urothelial cancer

Dr. Galsky, Professor, Mount Sinai School of Medicine, tells us about the Phase 3 Mvigor130 study investigating the addition of ...

video

Jorge Cortes, MD, on the evolution of CAR-T cell therapies in hematologic malignancies management

Dr. Cortes, Director, Georgia Cancer Center, explains the evolution of CAR-T cell therapies in the management of hematologic malignancies and ...

video

Jorge Cortes, MD, discusses the take home message from the OPTIC study in CML patients for HCPs

Dr. Cortes, Director, Georgia Cancer Center, discusses the take home message from the OPTIC study in chronic lymphocytic leukemia (CML) ...

Related Videos

video-image

Matthew Galsky, MD, explains which biomarkers likely have the most predictive value

video-image

Robert Coleman, MD, FACOG, FACS, discusses the 2 recent FDA approvals for PARP inhibitors in ovarian cancer

video-image

Howard Hochster, MD, regarding abstract 4009 at ASCO20 looking at the use of ctDNA in CRC patients

video-image

Matthew Galsky, MD, shares the design and outcomes of the Javelin Bladder 100 study

video-image

Robert Coleman, MD, FACOG, FACS, explains the underlying biology of homologous recombination deficiency and how it applies to the management of ovarian cancer patients

video-image

Salvatore Sienna, MD, explains the mechanism of action of trastuzumab deruxtecan and it's promise

video-image

Matthew Galsky, MD, considers a new standard of maintenance with the Javelin study outcomes

video-image

Robert Coleman, MD, describes the overall survival outcomes of the Phase 3 SOLO2 clinical study

video-image

Salvatore Sienna, MD, on his study investigating trastuzumab deruxtecan in HER2+ mCRC patients

video-image

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

video-image

Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC

video-image

Salvatore Sienna, MD, discusses the incidence of HER2+ patients amongst CRC patients

video-image

Howard Hochster, MD, provides thoughts on the potential practice changing results of the Keynote-177 study

video-image

Salvatore Sienna, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical development

video-image

Thierry Andre, MD, shares design of the Keynote-177 study in metastatic colorectal cancer

video-image

Howard Hochster, MD, on identifying patients that are MSI-H and unlikely to respond to pembrolizumab

video-image

Jorge Cortes, MD, tells us about the OPTIC study, a phase 2 investigation of ponatinib in CML

video-image

Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely respond to I-O

video-image

Howard Hochster, MD, discusses evolution of I-O toward first line treatment of colorectal cancer

video-image

Jorge Cortes, MD, provides thoughts on what the impact of the OPTIC study will be on CML patients